Your browser is no longer supported. Please, upgrade your browser.
Settings
ADXS Advaxis, Inc. daily Stock Chart
ADXS [NASD]
Advaxis, Inc.
Index- P/E- EPS (ttm)-2.37 Insider Own0.20% Shs Outstand55.18M Perf Week-2.31%
Market Cap93.25M Forward P/E- EPS next Y-1.81 Insider Trans-26.81% Shs Float47.77M Perf Month-10.58%
Income-96.80M PEG- EPS next Q-0.46 Inst Own30.70% Short Float8.07% Perf Quarter-44.22%
Sales10.30M P/S9.05 EPS this Y-11.00% Inst Trans-2.32% Short Ratio3.80 Perf Half Y-51.71%
Book/sh0.95 P/B1.78 EPS next Y3.20% ROA-92.30% Target Price9.50 Perf Year-79.66%
Cash/sh1.06 P/C1.60 EPS next 5Y- ROE-149.10% 52W Range1.51 - 9.55 Perf YTD-40.49%
Dividend- P/FCF- EPS past 5Y14.30% ROI-173.30% 52W High-82.30% Beta1.22
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low11.92% ATR0.11
Employees108 Current Ratio3.00 Sales Q/Q-44.70% Oper. Margin- RSI (14)45.54 Volatility5.06% 7.13%
OptionableYes Debt/Eq0.00 EPS Q/Q-16.20% Profit Margin- Rel Volume0.33 Prev Close1.64
ShortableYes LT Debt/Eq0.00 EarningsMar 12 AMC Payout- Avg Volume1.02M Price1.69
Recom1.50 SMA20-1.37% SMA50-13.71% SMA200-55.19% Volume341,367 Change3.05%
Aug-03-16Reiterated Barclays Overweight $15 → $20
Sep-22-15Initiated Barclays Overweight $40
Sep-11-15Initiated Guggenheim Buy $30
Jun-16-15Reiterated H.C. Wainwright Buy $25 → $30
May-15-15Initiated Jefferies Buy $27
May-14-15Initiated MLV & Co Buy $34
Oct-23-14Initiated H.C. Wainwright Buy $8
Feb-18-14Initiated Aegis Capital Buy $18
Feb-10-14Initiated Noble Financial Buy $12
Apr-23-18 08:00AM  Advaxis Announces Executive Leadership Changes Business Wire
Apr-17-18 08:00AM  Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting Business Wire
Apr-03-18 04:39PM  What Is The Future Prospect For Healthcare And Advaxis Inc (NASDAQ:ADXS)? Simply Wall St.
Apr-02-18 08:00AM  Data Highlighting Advaxis ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting Business Wire -5.92%
Mar-29-18 07:00AM  Wired News Recro Pharma Publishes Data from Phase-III Trial for IV Meloxicam ACCESSWIRE
Mar-26-18 06:28PM  Advaxis Inc (NASDAQ:ADXS): Does The -36.80% Earnings Drop Reflect A Longer Term Trend? Simply Wall St.
08:00AM  Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018 Business Wire
Mar-13-18 09:05AM  Edited Transcript of ADXS earnings conference call or presentation 12-Mar-18 8:30pm GMT Thomson Reuters StreetEvents -11.76%
08:00AM  Advaxis to Present at Upcoming March Conferences Business Wire
Mar-12-18 05:19PM  Advaxis shares drop as cancer-drug study on hold after death MarketWatch
04:31PM  Advaxis reports 1Q loss Associated Press
04:05PM  Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZenecas IMFINZI® (Durvalumab) Business Wire
08:54AM  Should You Have Advaxis Incs (NASDAQ:ADXS) In Your Portfolio? Simply Wall St.
Mar-09-18 11:06AM  How Do Analysts See Advaxis Inc (NASDAQ:ADXS) Performing Over The Next Few Years? Simply Wall St. +8.37%
08:00AM  Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018 Business Wire
Mar-08-18 10:27AM  Advaxis Inc (NASDAQ:ADXS): Is Breakeven Near? Simply Wall St.
Feb-22-18 01:05PM  Advaxis looks to raise $20 million via share offering American City Business Journals -28.29%
09:15AM  Advaxis Prices $20.0 Million Public Offering of Common Stock Business Wire
Feb-21-18 04:05PM  Advaxis Announces Proposed Public Offering of Common Stock Business Wire
Feb-13-18 08:30AM  Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union Business Wire
Feb-12-18 09:15AM  Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer Business Wire +5.32%
08:25AM  Research Report Identifies Diebold, Liberty TripAdvisor, Paycom Software, BJ's Restaurants, Advaxis, and Sanmina with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jan-29-18 08:00AM  Data Highlighting Advaxis Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies Business Wire
Jan-25-18 08:00AM  Advaxis Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology Business Wire
Dec-27-17 10:57AM  ETFs with exposure to Advaxis, Inc. : December 27, 2017 Capital Cube
Dec-26-17 09:16AM  Advaxis, Inc. :ADXS-US: Earnings Analysis: Q4, 2017 By the Numbers : December 26, 2017 Capital Cube
Dec-25-17 03:03PM  Edited Transcript of ADXS earnings conference call or presentation 21-Dec-17 3:00pm GMT Thomson Reuters StreetEvents
Dec-21-17 02:02PM  3 Stocks Move on Thursday GuruFocus.com -12.94%
Dec-20-17 04:15PM  Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update Business Wire +12.21%
08:05AM  Aratana Therapeutics Granted Conditional License for a Canine Osteosarcoma Therapeutic PR Newswire
06:05AM  Does Advaxis Incs (NASDAQ:ADXS) -20.1% EPS Decline Reflect A Long-Term Trend? Simply Wall St.
Dec-14-17 08:00AM  Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017 Business Wire
Dec-13-17 06:34PM  Is Advaxis Inc (NASDAQ:ADXS) As Financially Strong As Its Balance Sheet Indicates? Simply Wall St. +6.67%
Nov-22-17 07:50AM  Analysis: Positioning to Benefit within Diebold, Liberty TripAdvisor, Paycom Software, First American, Advaxis, and Sanmina Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-09-17 08:00AM  Advaxis to Present at the Jefferies 2017 London Healthcare Conference Business Wire
Nov-01-17 08:00AM  Advaxis to Receive $4.5 Million through the New Jersey Economic Development Authority NOL Program Business Wire -6.47%
Oct-03-17 07:20AM  Earnings Review and Free Research Report: Advaxis Reported its Q3 FY17 Results ACCESSWIRE
Sep-21-17 09:05AM  Advaxis to Webcast Company Overview at the Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-19-17 09:03AM  Two Abstracts Featuring Advaxis Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer (SITC) Meeting Business Wire
Sep-18-17 09:02AM  Advaxis to Present at Cantor Fitzgerald Global Healthcare Conference Business Wire
07:30AM  Corporate News Blog - EMA Grants Positive CHMP Opinion to Tesaros Ovarian Cancer Drug ACCESSWIRE
Sep-13-17 08:20AM  Today's Research Reports on Stocks to Watch: Advaxis and Heat Biologics ACCESSWIRE -11.31%
Sep-12-17 12:34PM  Here's Why Advaxis, Inc. Stock Is Getting Pummeled Today Motley Fool -19.88%
Sep-11-17 09:39PM  Advaxis reports 3Q loss Associated Press -7.69%
04:01PM  Advaxis Reports Business Update and Third Quarter 2017 Results Business Wire
Sep-08-17 07:20PM  What Does Advaxis Incs (ADXS) Share Price Indicate? Simply Wall St.
Aug-02-17 08:59AM  Advaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival Business Wire
Jul-13-17 09:06AM  Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders Business Wire +5.52%
Jul-06-17 04:48PM  Advaxis CEO Daniel O'Connor resigns Reuters
04:30PM  Advaxis Announces Change in Leadership Business Wire
Jun-26-17 08:55AM  Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 Business Wire
Jun-16-17 09:58AM  Advaxis Breaks Down From Key Support Levels Investopedia
08:00AM  Advaxis to Present at 2017 BIO International Convention Business Wire
Jun-15-17 12:54PM  ETFs with exposure to Advaxis, Inc. : June 15, 2017 Capital Cube -11.23%
Jun-14-17 08:00AM  Advaxis to Be Featured on Worldwide Business with kathy ireland® Business Wire -5.84%
Jun-13-17 12:30PM  Advaxis Details Registrational Trials, EU Regulatory and Commercial Plans at Annual Investor & Analyst Day Business Wire -7.82%
Jun-09-17 08:00AM  Advaxis to Webcast Investor & Analyst Day 2017 Business Wire -5.36%
Jun-08-17 09:17AM  Update: Webcast of Advaxis Presentation at Jefferies 2017 Global Healthcare Conference Now Available Business Wire
Jun-07-17 08:30AM  Advaxis to Present at Jefferies 2017 Global Healthcare Conference Business Wire
08:07AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : June 7, 2017 Capital Cube
05:01AM  Advaxis reports 2Q loss Associated Press
Jun-05-17 11:50AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Advaxis, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Jun-01-17 08:00AM  Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis' Clinical Trials PR Newswire
May-30-17 09:29AM  Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration TheStreet.com
06:59AM  Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo (nivolumab) in Metastatic Cervical Cancer Business Wire
05:17AM  How Two Biotechs Fell On Cancer Partnerships With Bristol-Myers Investor's Business Daily
May-18-17 08:00AM  Advaxis to Host Investor & Analyst Day on June 12 Business Wire +5.09%
May-15-17 09:03AM  Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac Business Wire
08:18AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : May 15, 2017 Capital Cube
May-05-17 10:00AM  Erin Andrews to Participate in Cervical Cancer Educational Forum Hosted by Sylvester Comprehensive Cancer Center and Gildas Club, Sponsored by Advaxis Business Wire
May-04-17 03:37PM  ETFs with exposure to Advaxis, Inc. : May 4, 2017 Capital Cube
Apr-28-17 04:32PM  Advaxis, Inc. Value Analysis (NASDAQ:ADXS) : April 28, 2017 Capital Cube
Apr-27-17 08:32AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : April 27, 2017 Capital Cube
08:00AM  Advaxis Recognized as One of New Jerseys Best Places to Work 2017 Business Wire
Apr-21-17 02:42PM  ETFs with exposure to Advaxis, Inc. : April 21, 2017 Capital Cube
Apr-19-17 08:00AM  Advaxis Appoints Anthony Lombardo as Chief Business Officer GlobeNewswire
Mar-27-17 03:47PM  ETFs with exposure to Advaxis, Inc. : March 27, 2017 Capital Cube
03:47PM  ETFs with exposure to Advaxis, Inc. : March 27, 2017
08:00AM  Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac GlobeNewswire
Mar-23-17 01:36PM  EMA Certification Paves Way for Advaxis Drug Investopedia
01:36PM  EMA Certification Paves Way for Advaxis Drug at Investopedia
08:00AM  EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer GlobeNewswire
Mar-22-17 09:22AM  Advaxis, Inc. :ADXS-US: Earnings Analysis: Q1, 2017 By the Numbers : March 22, 2017 Capital Cube
09:22AM  Advaxis, Inc. :ADXS-US: Earnings Analysis: Q1, 2017 By the Numbers : March 22, 2017
Mar-16-17 01:04PM  ADVAXIS, INC. Financials
Mar-15-17 07:00AM  Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGOs Annual Meeting on Womens Cancer GlobeNewswire
Mar-13-17 08:00AM  Advaxis to Present at the 2017 Barclays Global Healthcare Conference GlobeNewswire
Mar-10-17 07:48AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : March 10, 2017 Capital Cube
07:48AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : March 10, 2017
Mar-07-17 08:00AM  Advaxis Appoints Al Blunt, M.D., as its Vice President of Medical GlobeNewswire -8.65%
Mar-06-17 08:41AM  Advaxis stock jumps 10% after FDA okays clinical trials for Amgen-partnered cancer drug at MarketWatch
06:00AM  Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO GlobeNewswire
Mar-02-17 01:21PM  These 5 Stocks Under $10 Could Explode Up Soon
08:00AM  Advaxis to Host Research Reception at Society of Gynecologic Oncology Annual Meeting on Womens Cancer GlobeNewswire
Feb-28-17 10:31AM  Advaxis Inks Cancer Drug Deal with Sellas at Investopedia
Feb-27-17 08:00AM  Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy PR Newswire +6.74%
Feb-06-17 08:00AM  Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer GlobeNewswire
Jan-30-17 08:30AM  GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncologys Annual Meeting on Womens Cancer GlobeNewswire
Jan-26-17 07:46AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : January 26, 2017
Jan-25-17 08:00AM  New Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported GlobeNewswire
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PETIT ROBERTChief Scientific OfficerApr 02Sale1.622,1933,553223,500Apr 03 04:30 PM
LOMBARDO ANTHONY AInterim CEOFeb 02Sale2.93329492,903Feb 02 04:30 PM
Bonstein SaraChief Financial OfficerJan 03Sale3.185,22416,612224,013Jan 03 06:00 PM
Bonstein SaraChief Financial OfficerNov 06Sale3.303,86212,745227,908Nov 06 06:00 PM
PETIT ROBERTChief Scientific OfficerNov 06Sale3.303,72312,286220,917Nov 06 06:00 PM
LOMBARDO ANTHONY AInterim CEONov 02Sale3.19247792,935Nov 02 06:00 PM
PETIT ROBERTChief Scientific OfficerNov 02Sale3.1912,62540,274224,640Nov 02 05:54 PM
Bonstein SaraChief Financial OfficerNov 02Sale3.1912,73440,621231,770Nov 02 05:52 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerOct 11Sale4.30600,0002,580,0004,100,043Oct 12 03:53 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerSep 26Sale4.00300,0001,200,0004,700,043Sep 26 05:25 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerSep 25Sale4.38405,3231,775,3155,000,043Sep 26 05:25 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerSep 22Sale4.68534,0002,499,1205,405,366Sep 26 05:25 PM